10th Cir. Refuses Appeal of Sales Rep Ruling in Crestor Case

DENVER - A remand order based on fraudulent joinder of a pharmaceutical sales representative cannot be reviewed even where the trial court premised its ruling on the supposition that alleged defects in the plaintiffs' pleading would presumably be cured by an amended complaint, the 10th Circuit U.S. Court of Appeals has held. Nerad v. AstraZeneca Pharmaceuticals Inc., et al., No. 05-6128 (10th Cir.).

The federal appeals panel reached the decision in an Oct. 11 ruling that upheld the remand of Ron Nerad's personal injury suit against Crestor manufacturer AstraZeneca Inc. Nerad sued AstraZeneca and its sales representative in Oklahoma state …